Jean STEPHENNE

Jean Stéphenne joined GSK in 1974 where he held a number of managerial positions in the Biological Division before being appointed CEO in 1990 and finally Chairman of GSK Vaccines and Senior Advisor to the CEO in 2012.

He was named Baron by King Albert II of Belgium in 2000 in recognition of his leading contribution to R&D and Industry in Belgium and received a Knighthood of the British Empire in 2014. 

He is currently President of the Board of Curevac, Nanocyl, Vesalius, BePharBel & BePharBel Manufacturing S, Bone Therapeutics and OncoDNA. 

Mr Stéphenne holds an Engineering Degree in Chemistry and Bioindustries and a special Degree in Business and Administration.